Note: Descriptions are shown in the official language in which they were submitted.
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-1-
Use of Calcitonin in Osteoarthritis
The present invention relates to a novel use of calcitonin in osteoarthritis,
and to methods of
treating and/or preventing osteoarthritis in mammals, particularly humans.
Calcitonins, e.g. salmon, (Asu 1-7)-eel or human calcitonin, of the invention
are compounds
which are long-chain polypeptide hormones secreted by the parafollicular cells
of the thyroid
gland in mammals and by the ultimobranchial gland of birds and fish.
Calcitonin is mainly
known as a potent inhibitor of osteoclastic bone resorption, which implicates
bone
attachment of osteoclasts and enzymatic degradation. Furthermore, it was found
that there
are effects of Intranasal Salmon Calcitonin in Juvenile Idiopathic Arthritis
in humans
(Siamopoulou A. et al, 2001, Calcif Tissue Int 69: 25-30) and in the
prevention of bone
erosion and bone loss in rheumatoid arthritis in humans (Sileghem A., 1992,
Annals of
Rheumatic Diseases 51: 761-764). The degradative process associates synthesis
of various
proteases and metalloproteinases, activation of inactive proenymes and
inhibition of active
enzymes (Leloup G, 1994, J Bone Miner Res, 9, 891-902). Calcitonin is known to
induce
osteoclast retraction (Zheng MH, et al., 1992, Exper Mole Pathol, 57: 105-115)
and to
interfere at least with some steps of the enzymatic process of bone resorption
(Einhorn TA et
al., 1991, Clin Orthop 262: 286-297). There are some reported studies on the
effects of
calcitonin on articular cartilage. In vitro, calcitonin was found to stimulate
proteoglycan and
collagen synthesis in animal epiphyseal cartilage (Baxter et al., 1984,
Endocrinology 114:
1196-1202) as well as in rabbit and human cartilage (Franchimont P, 1989, J
Clin End Metab
69: 259-266). The study of calcitonin in the treatment of experimental
osteoarthritis gave
conflicting results. E.g. calcitonin was found to prevent cartilage
destruction in rabbits treated
with steroids, partial menisectomy or joint immobilization (Badurski JE et
al., 1991, Lab
Invest 49: 27-34), but no effect on cartilage was observed in another
menisectomy model
(Colombo et al., 1983, Arthritis Rheum 26: 1132-1139). Moreover, the relative
importance of
cartilage and bone changes in the initiation and progression of osteoarthritis
is still being
debated. No study in humans has yet shown to our knowledge the efficacy of
calcitonin in
osteoarthritis.
In accordance with the present invention, it has now surprisingly been found
that calcitonin,
e.g. salmon, (Asu 1-7)-eel or human calcitonin are useful in the prevention
and treatment of
osteoarthritis in mammals, particularly humans. In particular, the oral
delivery of calcitonin,
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-2-
e.g. salmon calcitonin or (Asu 1-7)-eel calcitonin, as described in the
present invention
shows such an effect. Said oral delivery of calcitonin is generally the
delivery route of choice
since it is convenient, relatively easy and generally painless, resulting in
greater patient
compliance relative to other modes of delivery.
In accordance with the particular findings of the present invention, there is
provided:
1.1. A method of preventing or/and treating osteoarthritis in a patient in
need thereof
comprising administering to said patient a therapeutically effective amount of
calcitonin, e.g.
salmon calcitonin in free form or salt form, preferably in a pharmaceutically
acceptable oral
delivery form;
1.2 A method of preventing or/and treating osteoarthritis in a patient in need
thereof
comprising administering to said patient a therapeutically effective amount of
calcitonin, e.g.
salmon calcitonin in free form or salt form, preferably in a pharmaceutically
acceptable oral
delivery form, wherein the therapeutically effective amount of a calcitonin is
delivered orally
in a composition comprising the calcitonin and a delivery agent for
calcitonin.
1.3 A method of preventing or/and treating osteoarthritis in a patient in need
thereof
comprising administering to said patient a therapeutically effective amount of
calcitonin, e.g.
salmon calcitonin in free form or salt form, preferably in a pharmaceutically
acceptable oral
delivery form, wherein the therapeutically effective amount of a calcitonin is
delivered orally
in a composition comprising the calcitonin which is conjugated to a polymer
molecule.
1.4 A method of inhibiting resorption and normalizing turnover of sub-chondral
bone in a
patient in need thereof comprising administering to said patient a
therapeutically effective
amount of calcitonin, e.g. salmon calcitonin in free form or salt form,
preferably in a
pharmaceutically acceptable oral delivery form;
1.5 A method of preserving and stimulating cartilage via a direct or indirect
effect on
chondrocytes in a patient in need thereof comprising administering to said
patient a
therapeutically effective amount of calcitonin, e.g. salmon calcitonin in free
form or salt form,
preferably in a pharmaceutically acceptable oral delivery form;
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-3-
1.6 A method of inhibiting phospholipase A2 and/or collagenase activity in a
patient in
need thereof comprising administering to said patient a therapeutically
effective amount of
calcitonin, e.g. salmon calcitonin in free form or salt form, preferably in a
pharmaceutically
acceptable oral delivery form;
1.7 A method of stimulatory effect on glycosaminoglycan and/or proteoglycan
synthesis in
a patient in need thereof comprising administering to said patient a
therapeutically effective
amount of calcitonin, e.g. salmon calcitonin in free form or salt form,
preferably 'in a
pharmaceutically acceptable oral delivery form;
1.8 A method of acting on the inhomogeneity in density or stiffness of the
subchondral
bone in a patient in need thereof comprising administering to said patient a
therapeutically
effective amount of calcitonin, e.g. salmon calcitonin in free form or salt
form, preferably in a
pharmaceutically acceptable oral delivery form;
1.9 A method of acting on the inflammatory process, leading to attenuations on
pain in
motion and related symptoms (e.g. circumference of knee, flexion angle of the
knee,
swelling stiffness) in a patient in need thereof comprising administering to
said patient a
therapeutically effective amount of calcitonin, e.g. salmon calcitonin in free
form or salt form,
preferably in a pharmaceutically acceptable oral delivery form;
2.0 A method to reduce the degenerative change in the joint in a patient in
need thereof
comprising administering to said patient a therapeutically effective amount of
calcitonin, e.g.
salmon calcitonin in free form or salt form, preferably in a pharmaceutically
acceptable oral
delivery form;
2.1 A method as defined above, comprising co-administration of a
therapeutically effective
amount of calcitonin, e.g. salmon calcitonin in free form or salt form,
preferably in a
pharmaceutically acceptable oral delivery form, and a second drug substance,
said second
drug substance being a bone resorption inhibitor, bone forming drug or pain
reducing drug in
free form or salt form.
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-4-
In another aspect, the invention provides a particular dosage range for a
calcitonin, e.g.
salmon calcitonin, which is efficacious and well tolerated, i.e. safe for a
patient to take.
Preferred is a range between 0.4 and 2.5 mg of salmon calcitonin for a
patient, e.g. human,
e.g. an average human of about 70 kg. More preferred are doses around I mg,
e.g. between
0.8 and 1.2 mg. Also preferred are doses less than 1 mg but higher than 0.4
mg. Even more
preferred is a dose of about 1 mg, e.g. 1 mg. Most preferred is a dose of
about 1 mg, e.g.
between 0.8 and 1.2 mg, administered once per day to a patient in need
thereof.
Pharmaceutical compositions comprising said doses according to the invention
may be the
compositions as provided in the Examples but may be preferably oral
compositions, e.g.
compositions as defined in Example 8. The dosage regimen may be once a day or
twice a
day, preferably one in the morning and one in the evening.
2.2 A method of preventing or/and treating osteoarthritis in a patient in need
thereof
comprising administering to said patient a pharmaceutical composition
comprising between
0.4 and 2.5 mg, preferably between 0.8 and 1.2 mg, most preferred about I mg,
of a
calcitonin, e.g. salmon calcitonin.
2.3 A pharmaceutical composition comprising between 0.4 and 2.5 mg, preferably
between
0.8 and 1.2 mg, most preferred about 1 mg of a calcitonin, e.g. salmon
calcitonin.
2.4 The use of a calcitonin, e.g. salmon calcitonin, in the manufacture of a
medicament for
the treatment and/or prevention of osteoarthritis, wherein said calcitonin is
provided in a
pharmaceutical composition comprising between 0.4 and 2.5 mg, preferably
between 0.8.
and 1.2 mg, most preferred about 1 mg, of a calcitonin, e.g. salmon
calcitonin.
2.5 A pharmaceutical composition for use in treating or/and preventing
osteoarthritis
comprising between 0.4 and 2.5 mg, preferably between 0.8 and 1.2 mg, most
preferred
about 1 mg, of a calcitonin, e.g. salmon calcitonin.
Suitable second drug substances may include a calcitonin of different origin,
e.g. salmon,
(Asu 1-7)-eel or human calcitonin, a calcitonin analogue or derivative
thereof, a steroid
hormone, e.g. an estrogen, a partial estrogen agonist or estrogen-gestagen
combination, a
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-5-
SERM (Selective Estrogen Receptor Modulator) e.g. raloxifene, lasofoxifene,
TSE-424,
FC1271, Tibolone (Livial ), vitamin D or an analogue thereof or PTH, a PTH
fragment or a
PTH derivative e.g. PTH (1-84), PTH (1-34), PTH (1-36), PTH (1-38), PTH (1-
31)NH2 or
PTS 893, bisphosphonates (e.g. alendronate, risedronate, zoledronic acid,
ibandronate);
protease inhibitors, e.g. Cathepsin inhibitor, preferably a cathepsin K
inhibitor; PTH
releasers; SARMs (selective androgen receptor molecules); MMP inhibitors
(metalloprotease
inhibitors), strontium ranelate, COX-2 inhibitors, e.g. lumiracoxib (Prexige
), celecoxib
(Celebrex ), rofecoxib (Vioxx ), valdecoxib (Bextra ), etoricoxib (Arcoxia ),
or mixed COX-
1 and COX-2 inhibitors, e.g. diclofenac.
The terms "co-administration" or "combined administration" or the like as
utilized herein are
meant to encompass administration of the selected therapeutic agents to a
single patient,
and are intended to include treatment regimens in which the agents are not
necessarily
administered by the same route of administration or at the same time.
As alternative to the above the present invention also provides:
3. A calcitonin, e.g. salmon, (Asu 1-7)-eel or human calcitonin in free form
or salt form,
preferably in a pharmaceutically acceptable oral delivery form, for use in any
method as
defined under 1.1 to 2.2 above; or
4. A calcitonin, e.g. salmon, (Asu 1-7)-eel or human calcitonin in free form
or salt form,
preferably in a pharmaceutically acceptable oral delivery form, for use in the
manufacture of
a medicament in any indications as defined under 1.1 to 2.2 above; or
5. A pharmaceutical composition for use in any indications as defined under
1.1 to 2.2
above comprising a calcitonin, e.g. salmon, (Asu 1-7)-eel or human calcitonin
in free form or
salt form, preferably in a pharmaceutically acceptable oral delivery form,
together with one or
more pharmaceutically acceptable diluents or carriers therefore.
6. A pharmaceutical combination comprising:
a) a first agent which is a calcitonin, e.g. salmon, (Asu 1-7)-eel or human
calcitonin in free
form or salt form, preferably in pharmaceutically acceptable oral delivery
form, and
CA 02532565 2011-08-11
21489-10423
-6-
b) a co-agent which is bone resorption inhibitor, bone forming drug or pain
reducing
agent, e.g. as disclosed above.
7. A kit of parts for use in the prevention and/or treatment of
osteoarthritis,
said kit comprising:
a) a first agent which is a calcitonin, e.g. salmon, (Asu 1-7)-eel or human
calcitonin in
free form or salt form, preferably in pharmaceutically acceptable oral
delivery form,
and
b) a co-agent which is bone resorption inhibitor, bone forming drug or pain
reducing
agent, e.g. as disclosed above.
In an embodiment of the present invention, there is provided a pharmaceutical
composition comprising 0.4 to 2.5 mg of calcitonin and an oral delivery agent
of
formula I:
R4 0
R3 R'
N- yOH
H 0
R2 ( OH
R~
Formula I
or a hydrate or alcohol solvate thereof, wherein: R1, R2, R3, and R4 are
independently hydrogen, -OH, -NR6R7, halogen, C1-C4alkyl, or C1-C4alkoxy; R5
is a
substituted or unsubstituted C2-C16alkylene, substituted or unsubstituted
C2-C16alkenylene, substituted or unsubstituted C1-C12alkyl(arylene), or
substituted or
unsubstituted aryl(C1-C12alkylene); and R6 and R7 are independently hydrogen,
oxygen, or C1-C4 alkyl, for use in the treatment or/and prevention of
osteoarthritis in a
human patient in need thereof, wherein the calcitonin is for oral delivery.
CA 02532565 2011-08-11
21489-10423
-6a-
In an embodiment of the present invention, there is provided a pharmaceutical
composition comprising 0.4 to 2.5 mg of calcitonin and an oral delivery agent
of
formula I as described herein for use in inhibiting resorption and/or
normalizing
turnover of subchondral bone in a human patient in need thereof, wherein the
calcitonin is for oral administration.
In an embodiment of the present invention, there is provided a pharmaceutical
composition comprising 0.4 to 2.5 mg of calcitonin and an oral delivery agent
of
formula I as described herein for use in preserving or stimulating cartilage
via a direct
or indirect effect on chondrocytes in a human patient in need thereof, wherein
the
calcitonin is for oral administration.
In an embodiment of the present invention, there is provided use of 0.4 to 2.5
mg of
calcitonin and an oral delivery agent of formula I as described herein in the
manufacture of a medicament for the treatment or/and prevention of
osteoarthritis in
a human patient in need thereof, wherein the calcitonin is for oral delivery.
In an embodiment of the present invention, there is provided use of 0.4 to 2.5
mg of
calcitonin and an oral delivery agent of formula I as described herein in the
manufacture of a medicament for inhibiting resorption and/or normalizing
turnover of
subchondral bone in a human patient in need thereof, wherein the calcitonin is
for
oral administration.
In an embodiment of the present invention, there is provided use of 0.4 to 2.5
mg of
calcitonin and an oral delivery agent of formula I as described herein in the
manufacture of a medicament for preserving or stimulating cartilage via a
direct or
indirect effect on chondrocytes in a human patient in need thereof, wherein
the
calcitonin is for oral administration.
In an embodiment of the present invention, there is provided use of 0.4 to 2.5
mg of
calcitonin and an oral delivery agent of formula I as described herein in the
treatment
or/and prevention of osteoarthritis in a human patient in need thereof,
wherein the
calcitonin is for oral delivery.
CA 02532565 2011-08-11
21489-10423
- 6b -
In an embodiment of the present invention, there is provided use of 0.4 to 2.5
mg of
calcitonin and an oral delivery agent of formula I as described herein in
inhibiting
resorption and/or normalizing turnover of subchondral bone in a human patient
in
need thereof, wherein the calcitonin is for oral administration.
In an embodiment of the present invention, there is provided use of 0.4 to 2.5
mg of
calcitonin and an oral delivery agent of formula I as described herein in
preserving or
stimulating cartilage via a direct or indirect effect on chondrocytes in a
human patient
in need thereof, wherein the calcitonin is for oral administration.
CA 02532565 2011-08-11
21489-10423
-6c-
The term "patient" as used herein means a patient in need of being treated or
prevented
from osteoarthritis or any method as defined under 1.1 to 2.2 above, whereas
patient means
mammals, such as rodents, cows, pigs, dogs, cats, and primates, particularly
humans-
The term "pharmaceutical combination" as used herein means a product that
results from
the mixing or combining of more than one active ingredient and includes both
fixed and non-
fixed combinations of the active ingredients. The term "fixed combination"
means that the
active ingredients, e.g. salmon calcitonin and a co-agent, are both
administered to a patient
simultaneously in the form of a single entity or dosage. The term "non-fixed
combination"
means that the active ingredients, e.g. salmon calcitonin and a co-agent, are
both
administered to a patient as separate entities either simultaneously,
concurrently or
sequentially with no specific time limits, wherein such administration
provides therapeutically
effective levels of the 2 compounds in the body of the patient.
Preferably the calcitonin, e.g. salmon calcitonin in free form or in
pharmaceutically
acceptable salt form, is co-administered with a protease inhibitor, e.g.
cathepsin inhibitor,
e_g. cathepsin K inhibitor.
Utility of calcitonin, e.g. salmon calcitonin in free form or salt form,
preferably in
pharmaceutically acceptable oral delivery form for use in any method as
defined under 1.1 to
1.10, may be demonstrated in animal test methods as well as in clinic, for
example in
accordance with the method hereinafter described in Example B.
CA 02532565 2010-10-27
21489-10423
-7-
When the pharmacologically active agent is salmon calcitonin, the appropriate
dosage will,
of course, vary depending upon, for example, the host and the nature and
severity of the
condition being treated. However, in general, satisfactory results will be
obtained
systemically at daily dosages of from about 0.5 g/kg to about 10 g/kg animal
body weight,
preferably 1 p.g/kg to about 6 g/kg body weight. The pharmaceutically
acceptable inactive
excipients which are used in the formulation of calcitonin, e.g. in the oral
formulation of
calcitonin, may include polymers and inactive compounds which for example, aid
the
formulation or manufacturing of the solid oral dosage form contemplated by the
present
invention or which may aid the release of the solid oral composition in the
gastro-intestinal
environment. The pharmaceutically inactive ingredients, referred to above, for
example
optionally include crospovidones and povidones, which may be any crospovidone
and
povidone. Crospovidone is a synthetic crosslinked homopolymer of N-vinyl-2-
pyrrolidone,
also called 1-ethenyl-2-pyrrolidinone, having a molecular weight of 1,000,000
or more.
TM TM
Commercially available crospovidones include Polyplasdone XL, Polyplasdone XL-
10,
TM TM
Polyplasdone INF-10 available from ISP, Kollidon CL, available from BASF
Corporation. The
TM
preferred crospovidone is Polyplasdone XL. Povidone is a synthetic polymer
consisting of
linear 1 -vinyl-2-pyrrolidinone groups having a molecular weight generally
between 2,500 and
TM TM
3,000,000. Commercially available povidones include Kollidon K-30, Kollidon K-
90F
available from BASF Corporation and Plasdone K-30 and Plasdone K-29/32,
available from
ISP. As mentioned above, the crospovidones and povidones are commercially
available.
Alternatively, they may be synthesized by known processes. The crospovidone,
povidone or
combination thereof is generally present in the compositions in an amount of
from 0.5 to 50
percent by weight relative to the total weight of the overall pharmaceutical
composition,
preferably an amount of from 2 to 25 percent, more preferably 5 to 20 percent
by weight
relative to the total weight of the pharmaceutical composition.
The delivery agents useful in the formulation, e.g. the oral formulation, are
any agents useful
for delivering the particular pharmacologically active agent. Suitable
delivery agents are any
one of the modified amino acids disclosed in aforementioned U.S. Patent No.
5,866,536 or
any one of the modified amino acids described In the aforementioned US Patent
No.
5,773,647 or any combination thereof.
In addition,
the delivery agent can be the disodium salt of any of the aforementioned
modified amino
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-8-
acids as well as ethanol solvates and hydrates thereof. Suitable compounds
include
compounds of the following formula I
R4 O
R3 R5 OH
H O
R OH
R1
Formula I
wherein
R1, R2, R3, and R4 are independently hydrogen, -OH, -NR 6R7, halogen, C1-
C4alkyl, or
C1-C4alkoxy;
R5 is a substituted or unsubstituted C2-C16alkylene, substituted or
unsubstituted C2-
C16alkenylene, substituted or unsubstituted C1-C12alkyl(arylene), or
substituted or
unsubstituted aryl(C1-C12alkylene); and
R6 and R7 are independently hydrogen, oxygen, or C1-C4 alkyl; and hydrates and
alcohol solvates thereof. The compounds of formula I as well as their disodium
salts and
alcohol solvates and hydrates thereof are described in WO 00/059863, along
with methods
for preparing them.
The disodium salt may be prepared from the ethanol solvate by evaporating or
drying the
ethanol solvate by methods known in the art to form the anhydrous disodium
salt. Drying is
generally carried out at a temperature of from about 80 to about 120 C,
preferably from
about 85 to about 90 C, and most preferably at about 85 C. The drying step
is generally
performed at a pressure of 26" Hg or greater. The anhydrous disodium salt
generally
contains less than about 5% by weight of ethanol and preferably less than
about 2% by
weight of ethanol, based on 100% total weight of anhydrous disodium salt. The
disodium salt
of the delivery agent can also be prepared by making a slurry of the delivery
agent in water
and adding two molar equivalents of aqueous sodium hydroxide, sodium alkoxide
or the like.
Suitable sodium alkoxides include, but are not limited to, sodium methoxide,
sodium
ethoxide, and combinations thereof. A still further method of preparing the
disodium salt is by
reacting the delivery agent with one molar equivalent of sodium hydroxide to
yield the
disodium salt. The disodium salt can be isolated as a solid by concentrating
the solution
containing the disodium salt to a thick paste by vacuum distillation. This
paste may be dried
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-9-
in a vacuum oven to obtain the disodium salt of the delivery agent as a solid.
The solid can
also be isolated by spray drying an aqueous solution of the disodium salt. The
delivery
agents may be prepared by methods known in the art, e.g., as mentioned above,
by
methods described in US Patent Nos. 5,773,647 and 5,866,536. The ethanol
solvates, as
described in the aforementioned WO 00/059863, include, but are not limited to,
a molecular
or ionic complex of molecules or ions of ethanol solvent with molecules or
ions of the
disodium salt of the delivery agent. Typically, the ethanol solvate contains
about one ethanol
molecule or ion for every molecule of disodium salt of the delivery agent. The
ethanol solvate
of the disodium salt of the delivery agent can be prepared by dissolving the
delivery agent in
ethanol. Typically, each gram of delivery agent is dissolved in from about 1
to about 50mL
of ethanol and generally, from about 2 to about 1 OmL of ethanol. The delivery
agent/ethanol
solution is then reacted with a molar excess of a sodium containing salt, such
as a
monosodium containing salt, relative to delivery agent, i.e. for every mole of
delivery agent
there is more than one mole of sodium cations, yielding the ethanol solvate.
Suitable
monosodium salts include, but are not limited to, sodium hydroxide; sodium
alkoxides, such
as sodium methoxide and sodium ethoxide; and any combination of the foregoing.
Preferably, at least about two molar equivalents of the monosodium containing
salt are
added to the ethanol solution, i.e. for every mole of delivery agent there is
at least about two
moles of sodium cations. Generally, the reaction is performed at or below the
reflux
temperature of the mixture, such as at ambient temperature. The ethanol
solvate is then
recovered by methods known is the art, such as, concentration of the resulting
slurry at
atmospheric distillation, cooling the concentrated slurry and filtering the
solid. The recovered
solid can then be vacuum dried to obtain the ethanol solvate. The hydrates of
the disodium
salts of the delivery agents may be prepared by drying the ethanol solvate to
from an
anhydrous disodium salt, as described above, and hydrating the anhydrous
disodium salt.
Preferably, the monohydrate of the disodium salt is formed. Since the
anhydrous disodium
salt is very hydroscopic, the hydrate forms upon exposure to atmospheric
moisture.
Generally, the hydrating step is performed at from about ambient temperature
to about 50 C,
preferably ambient temperature to about 30 C and in an environment having at
least 50%
relative humidity. Alternatively, the anhydrous disodium salt may be hydrated
with steam.
The preferred delivery agents are N-(5-chlorosalicyloyl)-8-aminocaprylic acid
(5-CNAC), N-
(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), N-(8-[2-
hydroxybenzoyl]amino)caprylic
acid (SNAC)and their monosodium and disodium salts, ethanol solvates of their
sodium salts
and the monohydrates of their sodium salts and any combinations thereof. The
most
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-10-
preferred delivery agent is the disodium salt of 5-CNAC and the monohydrate
thereof.
Preferably the disodium salt is present in amount of more than 90% weight per
total weight
of the 5-CNAC present in the composition. The delivery agent, 5 CNAC, SNAD,
and SNAC
are very water soluble and nearly fully, i.e. greater than 90%, absorbed by
the gastro-
intestinal tract whether it is ingested in micronized or coarse form. However,
it has been
found, surprisingly, that when a micronized form of one of these carrier
agents is employed
in the composition, the absorption of the pharmacologically active agent of
the present
composition is more completely absorbed into the blood stream. Therefore, the
use of
micronized carrier agent is a required element of the present invention. A
micronized form of
the carrier agent, which is utilized in preparation of the solid oral dosage
form of the present
invention, is defined as a carrier agent which, when added to the present
composition
mixture of pharmacologically active agent and pharmaceutically inactive
ingredients, has an
average particle size of less than 40 micrometers. Desirably the carrier agent
of the present
invention has a micronized form which is defined as an average particle size
of less than 20
microns. More interestingly, the carrier agent for the present invention has a
micronized
form which is defined as an average particle size of less than 10 microns.
Micronized forms
of the carrier agent of the present invention may be prepared by grinding it
in a grinding mill
which is acceptable for grinding pharmaceutical ingredients and which is
capable of grinding
the pharmaceutical ingredients and/or carrier agent to a fine and uniform
micronized particle
size. An example of such a grinding mill is an Air Jet Mill Gem T (Copley
Scientific, Ltd.,
Nottingham, UK). The finely ground carrier agent either separately or finely
ground carrier
agent plus any combination of finely ground additional ingredients of the
present invention
may then be screened, for example, over a mesh screen having the appropriate
openings, in
order to allow only those ingredients which have the required particle size to
pass through
and be collected for use in the present invention. The pharmaceutical
compositions of the
present invention typically contain a delivery effective amount of one or more
of the delivery
agents, i.e. an amount sufficient to deliver the active agent for the desired
effect. Generally,
the delivery agent is present in an amount of 2.5% to 99.4% by weight, more
preferably 25%
to 50% by weight.
Preferably a calcitonin, e.g. salmon calcitonin in free form or in salt form,
is delivered as a
pharmaceutical composition comprising calcitonin and a delivery agent for
calcitonin. More
preferably said pharmaceutical composition comprises a delivery agent selected
from the
group of 5-CNAC, SNAD, and SNAC. More preferably said pharmaceutical
composition
CA 02532565 2010-10-27
21489-10423
-11-
comprises a delivery agent is selected from the group consisting of a disodium
salt of 5-
CNAC, a disodium salt of SNAD, and a disodium salt of SNAC. More preferably,
said
pharmaceutical composition comprises a delivery agent in micronized form.
Alternatively, calcitonin can be orally delivered also with other technologies
such as the one
described in WO 94/26778; US 5,359,030; US 5,438,040; US 5,681,811; US
6,191,105; US
6,309,633; US 6,380,405; US 6,436,990; US 6,458,776; and US 6,479,692.
In short, such oral formulations
relate generally to conjugation-stabilized (poly)peptide and protein
compositions.
More particularly, such oral delivery forms relate in one broad compositional
aspect to
covalently conjugated calcitonin complexes wherein the calcitonin is
covalently bonded to
one or more molecules of a polymer incorporating as an integral part thereof a
hydrophilic
moiety, e.g., a linear polyalkylene glycol, and wherein said polymer
incorporates a lipophilic
moiety as an integral part thereof. In one particular aspect, such oral
delivery forms relate to
a physiologically active calcitonin composition comprising a physiologically
active peptide
covalently coupled with a polymer comprising (i) a linear polyalkylene glycol
moiety and (ii) a
lipophilic moiety, wherein the peptide, linear polyalkylene glycol moiety, and
the lipophilic
moiety are conformationally arranged in relation to one another such that the
physiologically
active peptide in the physiologically active calcitonin composition has an
enhanced in vivo
resistance to enzymatic degradation, relative to the physiologically active
calcitonin alone
(i.e., in an unconjugated form devoid of the polymer coupled thereto). In
another aspect,
such oral delivery forms relate to a physiologically active calcitonin
composition of three-
dimensional conformation comprising a physiologically active calcitonin
covalently coupled
with a polysorbate complex comprising (1) a linear polyalkylene glycol moiety
and (ii) a
lipophilic moiety, wherein the physiologically active calcitonin, the linear
polyalkylene glycol
moiety and the lipophilic moiety are conformationally arranged in relation to
one another
such that (a) the lipophilic moiety is exteriorly available in the three-
dimensional
conformation, and (b) the physiologically active calcitonin in the
physiologically active
calcitonin composition has an enhanced in vivo resistance to enzymatic
degradation, relative
to the physiologically active calcitonin alone. In a further aspect, such oral
delivery forms
relate to a multiligand conjugated calcitonin complex comprising a
triglyceride backbone
moiety, having: a bioactive calcitonin covalently coupled with the triglycedde
backbone
moiety through a polyalkylene glycol spacer group bonded at a carbon atom of
the
triglyceride backbone moiety; and at least one fatty acid moiety covalently
attached either
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-12-
directly to a carbon atom of the triglyceride backbone moiety or covalently
joined through a
polyalkylene glycol spacer moiety. In such multi ligand conjugated calcitonin
complex, the d
and B carbon atoms of the triglyceride bioactive moiety may have fatty acid
moieties
attached by covalently bonding either directly thereto, or indirectly
covalently bonded thereto
through polyalkylene glycol spacer moieties. Alternatively, a fatty acid
moiety may be
covalently attached either directly or through a polyalkylene glycol spacer
moiety to the a
and d carbons of the triglyceride backbone moiety, with the bioactive
calcitonin being
covalently coupled with the 13-carbon of the triglyceride backbone moiety,
either being
directly covalently bonded thereto or indirectly bonded thereto through a
polyalkylene spacer
moiety. In such a multiligand conjugated calcitonin complex, the bioactive
calcitonin may
advantageously be covalently coupled with the triglyceride modified backbone
moiety
through alkyl spacer groups, or alternatively other acceptable spacer groups,
within the
broad scope of the invention. As used in such context, acceptability of the
spacer group
refers to steric, compositional, and end use application specific
acceptability characteristics.
In yet another aspect such oral delivery forms relate to a polysorbate complex
comprising a
polysorbate moiety including a triglyceride backbone and functionalizing
groups including:
(i) a fatty acid group; and (ii) a polyethylene glycol group having a
physiologically active
moiety covalently bonded thereto, e.g., a physiologically active moiety is
covalently bonded
to an appropriate functionality of the polyethylene glycol group.
Such covalent bonding may be either direct, e.g., to a hydroxy terminal
functionality of the
polyethylene glycol group, or alternatively, the covalent bonding may be
indirect, e.g., by
reactively capping the hydroxy terminus of the polyethylene glycol group with
a terminal
carboxy functionality spacer group, so that the resulting capped polyethylene
glycol group
has a terminal carboxy functionality to which the physiologically active
moiety may be
covalently bonded. Such oral delivery forms relate to a further aspect to a
stable, aqueously
soluble, conjugated calcitonin complex comprising a physiologically active
calcitonin
covalently coupled to a physiologically compatible polyethylene glycol
modified glycolipid
moiety. In such complex, the physiologically active calcitonin may be
covalently coupled to
the physiologically compatible polyethylene glycol modified glycolipid moiety
by a labile
covalent bond at a tee amino acid group of the polypeptide. The
physiologically compatible
polyethylene glycol modified glycolipid moiety may advantageously comprise a
polysorbate
polymer, e.g. , a polysorbate polymer comprising fatty acid ester groups
selected from the
group consisting of monopalmitate, dipalmitate, monolaurate, dilaurate,
trilaurate,
monoleate, dioleate, trioleate, monostearate, distearate, and tristearate. In
such complex,
CA 02532565 2010-10-27
21489-10423
-13-
the physiologically compatible polyethylene glycol modified glycolipid moiety
may suitably
comprise a polymer selected from the group consisting of polyethylene glycol
ethers of fatty
acids, and polyethylene glycol esters of fatty acids, wherein the fatty acids
for example
comprise a fatty acid selected from the group consisting of lauric, palmitic,
oleic, and stearic
acids. In the above complex, the physiologically active calcitonin may by way
of illustration
comprise a calcitonin selected from the group consisting of insulin,
calcitonin, ACTH,
glucagon, somatostatin, somatotropin, somatomedin, parathyroid hormone,
erythropoietin,
hypothalmic releasing factors, prolactin, thyroid stimulating hormones,
endorphins,
enkephalins, vasopressin, non- naturally occurring opiods, superoxide
dismutase, interferon,
asparaginase, arginase, arginine deaminease, adenosine deaminase ribonuclease,
trypsin,
chemotrypsin, and papain. In another aspect, the present invention relates to
an oral
administration dosage form for the mediation of Insulin deficiency, comprising
a
pharmaceutically acceptable carrier and a stable, aqueously soluble,
conjugated insulin
complex comprising insulin or proinsulin covalently coupled to a
physiologically compatible
polyethylene glycol modified glycolipid moiety.
Furthermore, a further second alternative oral delivery dosage form which may
be used
according to the invention is a technology described in WO 97/33531; US
5,912,014 and US
608618. In short,
such further oral delivery form protects calcitonin from the acidic
environment and digestive
enzymes as it passes through the stomach and intestine, and facilitates its
entry into the
bloodstream. Once it is safely in the bloodstream, calcitonin can exert its
therapeutic effect.
Such oral delivery form is e.g. a pharmaceutical composition for oral delivery
of salmon
calcitonin comprising: (A) a therapeutically effective amount of said salmon
calcitonin; (B) at
least one pharmaceutically acceptable pH-lowering agent; (C) at least one
absorption
enhancer effective to promote bioavailability of said salmon calcitonin; and
(D) an enteric
coating; wherein said pH-lowering agent is present in said pharmaceutical
composition in a
quantity which, if added to 10 milliliters of 0.1 M aqueous sodium bicarbonate
solutions would
be sufficient to lower the pH of said solution to no higher than 5.5. The
pharmaceutical
composition, wherein said enteric coating is present at a weight which is no
more than 20%
of the weight of the remainder of said pharmaceutical composition excluding
said enteric
coating. The pharmaceutical composition of above, wherein said enteric coating
is present at
a weight which is no more than 5-15% of the weight of the remainder of said
pharmaceutical
composition excluding said enteric coating.
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-14-
The pharmaceutical compositions with which the usefulness of calcitonin in the
treatment of
osteoarthritis is shown, may be provided as a capsule including a soft-gel
capsule, tablet,
caplet, suppository or other solid oral dosage form, all of which can be
prepared by methods
well known in the art.
The solid pharmaceutical compositions of the instant invention can be prepared
by first
grinding either the carrier agent or the carrier agent with any combination of
the additional
ingredients of the present composition to a micronized particle size. The
micronized carrier
agent or micronized carrier agent plus micronized additional ingredients of
the present
invention may then be further processed by conventional methods e.g. by
blending a mixture
of the active agent or active agents, the delivery agent, the crospovidone or
povidone and
other ingredients, kneading, and filling into capsules or, instead of filling
into capsules,
molding followed by further tableting or compression-molding to give tablets.
In addition, a
solid dispersion may be formed by known methods followed by further processing
to form a
tablet or capsule.
The following examples serve to further illustrate the invention and will be
readily understood
by one of ordinary skill in the art. The examples are not meant to be limiting
of the present
invention in any way.
CA 02532565 2010-10-27
21489-10423
-15-
Examples
A. Formulation Examples
EXAMPLE 1: Formulation 1 (3 batches)
Preparation of Micronized 5-CNAC: Coarse 5-CNAC, which is to be micronized, is
added to
a jet mill (Air Jet Mill Gem T Copley Scientific, Ltd., Nottingham, UK)
using a 80 ceramic
pan cake jet mill, 8 cm diameter, 6 bar N2, 0.5 mm nozzles with manual feed of
about 700
g/h. The coarse 5-CNAC is jet milled and periodically sampled under microscope
with
reference ruler measurements to identify when the average desired micronized
particle size
is obtained. Three different batches are ground to create 6 um, 35 um, and 46
urn batches.
Individual sieving of the separate micronized batches is then done by using a
conical sieve
mill (Quadro Comil, Quadro Engineering Incorporated 613 Colby Drive, Waterloo,
Ontario,
Canada N2V IA1) with a U10, 813 um conical sieve, round beater, operating at
1500 upm
with throughput of about 150 kg/h.
Formulation 1-3. Salmon Calcitonin Formulation with 5-CNAC of Different
Particle
Size
Ingredient Amount (mg) Percent (%)
Salmon Calcitonin 1 0.25
Micronized 5-CNAC 228 57
TM
Avicel PH 102 147 36.75
Crospovidone, NF 20 5
Magnesium stearate 4 1
Total 400 100
Preparation of Formulation 1: Three different batches of tablets are prepared
using the three
different batches of micronized 5-CNAC disodium, one tablet batch having an
average 5-
CNAC disodium particle size of 46 microns (Batch A), a second tablet batch
having an
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-16-
average 5-CNAC disodium particle size of 6 microns (Batch B), and a third
tablet batch
having an average 5-CNAC disodium particle size of 35 microns (Batch C).
0.50 g of salmon calcitonin, pre-screened through a 40 mesh screen, 57. g of
micronized 5-
CNAC disodium salt, screened through a 35 mesh screen, and 10 g of
Polyplasdone XL
(crospovidone, NF, International Specialty Products, 1361 Alps Road, Wayne,
New Jersey,
07470, USA) is combined in a 500 mL jar and is mixed using a Turbula mixer for
100
revolutions at a speed of 46 RPM. An additional 57. g of micronized 5-CNAC
disodium salt,
screened through a 35 mesh screen, and 36.75 g of Avicel PH 102 is added to
the jar and
mixed for 500 revolutions at a speed of 46 RPM. A further 36.75 g of Avicel PH
102 is
added to the jar and is mixed for an additional 100 revolutions at a speed of
46 RPM. 4.0 g
of magnesium stearate is screened into the jar using a 35 mesh screen and is
blended for 1
minute at a speed of 46 RPM. The final blend is compressed into tablets using
a Manesty
B3B tablet press. The tablet weight is approximately 400 mg.
The bioavailability of the tablets created in Example 1 may be tested as
follows:
EXAMPLE 2
Primate Administration
The tablets are prepared as in Example 1 using three different batches of
micronized
5-CNAC disodium, one tablet batch having an average 5-CNAC disodium particle
size of 46
microns (Batch A), a second tablet batch having an average 5-CNAC disodium
particle size
of 6 microns (Batch B), and a third tablet batch having an average 5-CNAC
disodium particle
size of 35 microns (Batch C). The tablets prepared from each of the three
different batches
are administered to the same four Rhesus monkeys separately on different days
as follows:
The Rhesus monkeys fast overnight prior to dosing and are restrained in chairs
fully
conscious, for the duration of the study period. One tablet from Batch A or
Batch B or Batch
C is administered to each monkey via a gavage tube followed by 10 mL of water.
Rhesus monkey blood samples are collected immediately before administration
and
at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, and 6 hours after administration. A
tablet from each of
the remaining two tablet batches is dosed and blood samples are collected in a
similar
manner but on a separate day for each of the remaining tablet batches.
Resulting plasma
salmon calcitonin for each dose and for each monkey is determined by
radioimmunoassay.
For each monkey, the primate plasma salmon calcitonin (SCt) for one batch and
one time
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-17-
period, mean plasma SCt concentrations for all monkeys for one batch and one
time period,
Standard Deviation (SD) of plasma SCt concentrations for one batch and one
time period,
and Standard Error of the Mean (SEM) for plasma SCt concentrations for all
monkeys for
one batch and one time period are calculated and reported in Tables 1, 2, and
3 as follows.
TABLE 1 BATCH A: AVERAGE 5-CNAC PARTICLE SIZE 46 MICROMETERS
Salmon Calcitonin (SCt) Plasma Concentrations [pg/mL]
(Single Oral Tablet (200 mg 5-CNAC + 1 mg SCt) to the Rhesus Monkey)
Animal Time [hours]
no. 0 0.25 0.50 0.75 1 1.5 2 3 4 5 6
1 0.0 17.8 91.7 279.7 449.2 278.8 48.0 10.5 5.3 3.3 0.0
2 0.0 117.4 535.0 430.8 981.4 1718.0 2396.4 719.5 253.6 102.1 62.9
3 0.0 113.9 754.5 1502.0 2351.0 2066.0 2684.4 1310.0 649.6 280.6 156.5
4 0.0 46.0 127.0 425.5 765.8 1102.0 1599.0 1022.0 419.3 87.0 23.4
Mean 0.0 73.8 377.1 659.5 1136.9 1291.2 1682.0 765.5 332.0 118.3 60.7
SD 0.0 49.7 322.2 566.0 838.4 783.8 1182.1 558.1 271.6 116.6 68.9
SEM 0.0 24.9 161.1 283.0 419.2 391.9 591.0 279.0 135.8 58.3 34.5
Lower Limit of Quantification (LLOQ) = 2.5 pg/mL, concentrations below LLOQ
were set to zero for Table 1
TABLE 2 BATCH B: AVERAGE 5-CNAC PARTICLE SIZE 6 MICROMETERS
Salmon Calcitonin (SCt) Plasma Concentrations [pg/mL]
(Single Oral Tablet (200 mg 5-CNAC + I mg SCt) to the Rhesus Monkey)
Animal Time [hours]
no. 0 0.25 0.50 0.75 1 1.5 2 3 4 5 6
1 0.0 265.6 315.8 245.6 357.2 1927.0 3010.0 863.2 139.4 48.5 20.8
2 0.0 607.0 777.0 1336.0 1602.0 4146.0 7521.0 2681.0 420.8 73.9 43.2
3 0.0 80.9 225.5 325.6 655.6 1478.0 3979.0 2775.0 520.2 91.5 41.3
4 0.0 286.4 155.3 237.7 241.0 269.7 294.2 321.0 179.8 67.5 13.6
Mean 0.0 310.0 368.4 536.2 714.0 1955.2 3701.1 1660.1 315.1 70.4 29.7
SD 0.0 218.5 280.2 534.7 617.2 1619.6 2986.3 1253.5 184.8 17.8 14.8
SEM 0.0 109.2 140.1 267.3 308.6 '809.8 1493.1 626.7 92.4 8.9 7.4
CA 02532565 2010-10-27
21489-10423
-18-
Lower Limit of Quantification (LLOQ) = 2.5 pg/mL, concentrations below LLOQ
were set to zero for Table 2
TABLE 3 BATCH C: AVERAGE 5-CNAC PARTICLE SIZE 35 MICROMETERS
Salmon Calcitonin (SCt) Plasma Concentrations [pg/mL].
(Single Oral Tablet (200 mg 5-CNAC + I mg SCt) to the Rhesus Monkey)
Animal Time [hours]
no. 0 0.25 0.50 0.75 1 1.5 2 3 4 5 6
1 0.0 36.1 94.7 428.0 739.4 2568.0 4025.0 1348.0 499.6 218.4 98.1
2 0.0 10.9 55.0 168.9 248.2 507.3 654.0 434.8 177.3 68.8 38.9
3 0.0 172.3 336.6 409.5 584.9 1487.0 2087.0 1479.0 162.0 52.0 17.2
4 0.0 7.9 46.9 208.1 390.1 1237.0 2347.0 1342.0 192.3 42.3 19.2
Mean 0.0 56.8 133.3 303.6 490.7 1449.8 2278.3 1151.0 257.8 95.4 43.4
SD 0.0 78.0 137.1 134.1 215.8 853.5 1382.1 481.6 161.7 82.7 37.8
SEM 0.0 39.0 68.6 67.1 107.9 426.7 691.1 240.8 80.8 41.4 18.9
Lower Limit of Quantification (LLOQ) = 2.5 pg/mL, concentrations below LLOQ
were set to zero for Table 3
EXAMPLE 3: Preparation of Formulations 2-4:
Alternatively, there are further formulations provided:
Formulation 2:
Ingredient Amount (mg)
sCT 0.25
5-CNAC (micronized) 28.5
Avicel PH102 238.25
Crospovidone XL 15
PluronicTM F68 3
Cab-O-SiITM 3
Talc 6
Mg Stearate 6
Total 300
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-19-
Formulation 3:
Ingredient Amount (mg)
sCT 0.5
5-CNAC (micronized) 28.5
Avicel PH102 238
Crospovidone XL 15
Pluronic F68 3
Cab-O-Sil 3
Talc 6
Mg Stearate 6
Total 300
Formulation 4:
Ingredient Amount (mg)
sCT 0.5
5-CNAC (non-micronized) 28.5
Avicel PH102 238
Crospovidone XL 15
Pluronic F68 3
Cab-O-Sil 3
Talc 6
Mg Stearate 6
Total 300
The process for preparation of the above formulations are similar to that of
the one,
described in Example 1. However, since there are a few more components for the
current
formula, there is some deviation which are described below:
1 Pre Weigh 0.3g of sCT, pass sCT through #60 mesh screen
2 Weigh 0.25 g of screened sCT DS
3 Blend sCT and Crospovidone in a suitable container using Turbula Mixer,
blend for
mins
4 Pass through #45 mesh screen
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-20-
Add 5-CNAC to Blend from step #3, blend for 10 mins
6 Pass through #35 mesh screen
7 Add half Avicel into Blend #5, blend for 10 mins
8 Pass through #35 mesh screen
9 Add remaining of Avicel, Pluronic F68, and Cab-O-Sil blend for 20 mins
Add Talc and Mg Stearate into the above blend and blend for 2 mins
All the equipments used are the same as described in Example 1.
EXAMPLE 4: Preparation of Formulation 5:
Alternative formulation is presented shortly presented below: 0.502 of salmon
calcitonin, pre-
screened through a 40 mesh screen, 120 g of 5-CNAC disodium salt, pre-screened
through
a 35 mesh screen, and 20 g of Polyplasdone XL (crospovidone, NF) is combined
in a 500
mL jar and is mixed using a Turbula mixer for 2 minutes at a speed of 46 RPM.
An additional
125.4 g of 5-CNAC disodium salt, pre-screened through a 35 mesh screen, and
32.5 g of
Avicel PH 102 is added to the jar and is mixed for a period of 8 minutes at a
speed of 46
RPM. A further 32.5 g of Avicel is added to the jar and is mixed for 5 minutes
at a speed of
46 RPM. 4.0 g of magnesium stearate is screened into the jar using a 35 mesh
screen and
is blended for 1 minute at a speed of 46 RPM. The final blend is compressed
into tablets
using a Manesty B3B tablet press. The tablet weight is approximately 400 mg.
EXAMPLE 5: Preparation of Formulation 6:
An alternative formulation comprising salmon calcitonin suitable for nasal
administration:
Ingredient Quantity (per ml)
1) Salmon calcitonin (active ingredient) 0.1375 mg
10% excess 0.01375 mg
0.15125 mg
2) NaCl 7.5 mg
3) Benzalkonium chloride 0.1 mg
4) HCI (1 N) added to pH 3.7
CA 02532565 2010-10-27
21489-10423
-21 -
5) Distilled water to an end volume of 1.0 ml.
Components 1 to 3 are combined under protection of nitrogen gas (on a scale to
produce a
final volume of 2500 mi) in conventional manner, with 10% of salmon calcitonin
being added
to allow for loss at filtration. 4) is then added to bring the pH to 3.7 and
distilled water added
to an end-volume of 2500 mi. The obtained solution is filtered (e. g. using a
0.2 mu.m filter)
to give a composition suitable for nasal application and for filling into a
spray nasal dispensor
with a solution volume of 2 ml.
EXAMPLE 6: Preparation of Formulation 7:
Suppositories containing 300 I.U. (international Units) of salmon calcitonin
are prepared
according to e.g. US 5149537 containing
the following composition per suppository:
Ingredient Mg/Suppository
Salmon calcitonin (300 I.U.) 0.0692+ (1mg substance contains 4767
I.U. (overage of 10% used)
Anhydrous citric acid 0.78
Trisodium citrate dehydrate 0.50
Mannitol 48.651
Sodium taurocholate 30.0
Suppository base A 1420.0
1500 mg
As suppository base A may be used cocoa butter. It is preferred to use
synthetic or semi-
synthetic suppository bases. These may be water insoluble fats, e.g.
glycerides (mono-, di-
and/or tri-) of fatty acids, e.g. made from coconut oil or palm kern oil.
Straight Chain C10-18 fatty acid glycerides, conveniently saturated are
preferred.
Examples are Witepsol (Registered Trade Mark), e.g. Witepsol H series
available from
Dynamit Nobel, W. Germany; Suppocire (Registered Trade Mark), e.g. Suppocire
AM or
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-22-
AS2, available from Gattefosse, France and Novata (Registered Trade Mark),
e.g. Novata
BD, available from Henkel GmbH, W. Germany.
Alternatively, the Guerbet alcohols and water soluble suppository bases such
as
polyethyleneglycol may be used.
Preferably the suppository base has a low melting range, e.g. 30 to 36 C.
Preparation procedure
a) Preparation of granulate (for 3,500 doses)
0.2423 g of the calcitonin, 2.73 g of the citric acid, 1.75 g of the tri-
sodium salt are mixed in
the dry state and dissolved in 14.0 g water. 170.3 g of sieved mannitol is
added (AS 700
microns, WD 120 microns). The mass is kneaded and sieved (AS 1,600 microns, WD
450
microns). The des-agglomerated powder is dried at 40. C. for 25 minutes, and
sieved (AS
450 microns, AS 120 microns) to give 167 g of a powder.
b) Addition of enhancer and molding (for 3,000 doses)
150 g of the powder obtained from step a) and 90 g of ground sodium
taurocholate as
mixed, sieved (AS 250; WD 100 microns), and mixed again. The mixture is added
to 4260 g
of melted suppository base A at 38 C. Homogenization is effected (Polyton
apparatus,
speed setting 4) for 3 minutes. The mass is transferred at 33 C. to a pre-
warmed vessel in
a suppository making machine (BONAPACE).
The suppositories are molded at from 33 to 33.5 C. in neutral
polyvinylchloride foil (or
aluminium foil) in doses of about 1.5 ml and weight 1.5 g. Cooling is effected
with an air
stream at 20 C. Yield 2,590 suppositories. Disintegration time 6 minutes.
Melting point 34.9
C. Hardness 81 N at 20 C, pH in water 4.2.
B. Example showing efficacy of calcitonin in osteoarthritis:
EXAMPLE 7: Clinical Trial
36 osteoarthritic patients completing the trial are included in a 12 weeks (84
days) double
blind, placebo controlled, monocenter, parallel study. The objective is to
assess in vivo the
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-23-
effects of an oral formulation of calcitonin on biochemical markers of bone,
cartilage and
synovium metabolism in human osteoarthritis. Patients are devided in three
groups: two
groups treated with oral calcitonin either 0.5 mg or 1 mg once daily and one
control group
receiving a placebo.
The inclusion criteria are (table 4):
= Females either over 55 years of age or over 50 years of age and at least 5
years
menopausal (natural or surgical).
= Males over 50 years of age. Those having intercourse with a woman who is not
postmenopausal will have to use barrier contraception during the whole time
period
of the study and continuing for 4 weeks after the completion of the study.
= Patients suffering from active osteoarthritis of the hip and/or knee.
Hyperactivity of
the diseased joint documented in recent (= 6 months before study start ) bone
scintigrams is mandatory.
= Patients with at least moderate pain on active movement (greater than or
equal at 10
on the LEQUESNE scale (see MG Lequesne, 1997, J of Rheumatology 24: 779-781)
= Patients having read the information sheet and signed the consent form.
The exclusion criteria are (table 5):
= Patients suffering from acute osteoarthritis and requiring intervention of
arthroplasty
during the course of the study or requiring joint immobilization for several
weeks prior
to or during the study period .
= Patients suffering from crystal deposit diseases or with known hereditary or
congenital defects.
= Patients suffering from clinical significant hepatic, renal, cardiovascular,
psychiatric,
endocrine and / or hematological diseases.
= Patients suffering from any other systemic or local disease judged to be
incompatible
with the present protocol by the Investigator.
= Patients with abnormal laboratory values judged as clinically significant
= Patients who have received any intra-articular injection or systemic
administration of
corticosteroids during the 8 weeks before the study start .
= Patients with a known history of alcohol and/or drug abuse or those unlikely
to
cooperate with the Investigator in accordance with the study protocol.
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-24-
The study end-points are (table 6):
= The primary study end-points are the circulating levels of the human markers
of
cartilage, synovium and bone metabolism.
= The secondary study end-points are the drug treatment efficacy and
tolerability, as
assessed by the patient and Investigator.
= Additionally safety assessments consist of monitoring and recording all
adverse
events and serious adverse events, the regular monitoring of hematology, blood
chemistry and urine values, regular measurement of vital signs and the
performance
of physical examinations.
The study procedure: Following a 2 weeks pre-treatment wash-out period, during
which only
paracetamol is allowed to be taken at the maximum daily dosage of 3000 mg,
each patient
is randomized to the intake of either placebo or one of the two dosages of the
oral
formulation of calcitonin. During the 12 weeks treatment period, the patient
is allowed to take
paracetamol in case of need at a maximum daily dosage of 3000 mg.
The patients' evaluation time-points are (table 7):
= Visit 1: day -14: Screening visit. Start of wash-out period.
= Visit 2: day 0: Baseline visit. Start of treatment.
= Visit 3: day 14: 2 weeks of treatment completed.
= Visit 4: day 42: 6 weeks of treatment completed.
= Visit 5: day 84: Final visit. 12 weeks of treatment completed.
The type of evaluations (table 8):
= At visits 2, 3, 4 and 5, the second fasting urine of the morning as well as
plasma,
serum and synovial fluid (if any) are sampled and analyzed for cartilage,
synovium
and bone metabolism markers by specific immunoassays.
= Adverse events are recorded at visits 3, 4 and 5 .
= One or more (knee or hip) joints are evaluated by the LEQUESNE questionnaire
at
visit 1 (screening visit), and documented as eligible for selection at the
next visit, on
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-25-
the basis of pain intensity under active movement. At visit 2 (baseline visit)
these
eligible joints are reassessed and the most painful joint for which the pain
intensity is
equal or above 10 on the LEQUESNE questionnaire, is selected as the target
joint.
= The drug efficacy on the target joint are made on the basis of the evolution
of the
pain intensity between visits 2 and 5 (related to the pain intensity at visit
1) by a
clinical examination and the LEQUESNE questionnaire.
= Regarding treatment efficacy evaluation, the quantity of rescue medication
(paracetamol) taken by the patient during,the 12 weeks treatment period is
considered.
= Drug efficacy and tolerability is additionally assessed and patient at
visits 3, 4 and 5
by means of 2 separate VAS scales (see Huskinson E.C., 1974, The Lancet: 1127-
1131)
Example 8: 3-month treatment with oral salmon calcitonin suppresses urinary
collagen type II degradation products in postmenopausal women
Subjects and Methods: The study population consists of 152 generally healthy
Danish
postmenopausal women 55-85 years old, who have been postmenopausal for at
least 5
years. Women receive treatment with either daily (0.15, 0.4, 1.0, or 2.5 mg)
orally dosed sCT
(see below for pharmaceutical compositions) combined with eligen technology-
based carrier
molecule (200 mg), or placebo for 3 months. All participants receive a calcium
supplement of
1000 mg plus 400 IU of vitamin D daily throughout the study. Efficacy
parameters are 24
hours urinary C-terminal telopeptide of collagen type I (CTX-I) and CTX-II
corrected for
creatinine excretion assessed at baseline and after 3-month therapy.
Pharmaceutical Compositions comprising salmon calcitonin used in study
Ingredient Amount per tablet (mg)
Salmon Calcitonin 0.15 0.4 1 2.5
5-CNAC-disodium salt 228 228 228 228
(non-micronized)
Microcrystalline cellulose, NF 147. 147.6 147 145.5
(Avicel PH-102) 85
Crospovidone, NF 20 20 20 20
Magnesium Stearate, NF, EP 4 4 4 4
Total 400 400 400 400
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-26-
Manufacturing process:
i) Weigh 5-CNAC and divide into 2 equal parts and label as A and B.
ii) Weigh Avicel and divide into 2 equal parts and label as A and B.
1) Place crospovidone on a 35 mesh screen. Place pre-weighed calcitonin on top
of
crospovidone, then add part A of 5-CNAC .
2) Screen crospovidone/calcitonin/5-CNAC and transfer into suitable size
blender and blend
for 500 revolutions.
3) Screen part B of 5-CNAC through 35 mesh screen.
4) Add part B of screened 5-CNAC and part A of Avicel to mixed blend from step
2) and
blend for 800 revolutions.
5) Add part B of Avicel to above blend from step 4) and blend for 500
revolutions.
6) Screen magnesium stearate through 35 mesh screen and add to blended powders
from
step 5) and blend for 100 revolutions.
Results: There are no significant differences in the different intervention
groups of sCT in
terms of age, BMI, baseline urinary concentration of CTX-l and CTX-II . There
is a clear and
significant dose dependent relationship in 24 hours urinary CTX-II response to
oral sCT
(ANOVA=0.012). Compared to placebo, the 1.0 mg daily group reveales the
greatest
decrease in urinary CTX-II after 3-month treatment (-19.7%, p=0.009). The
women who
receive 0.4 mg and 2.5 mg of sCT also have significant decreases in urinary
CTX-ll (-15.2%,
p=0.04, and -17.5%, p=0.02, respectively). Similar dose-dependent responses
are found in
24-hour urinary CTX-I at 3-month treatment. Women receiving 1.0 mg of sCT also
have the
greatest reduction in 24-hours urinary CTX-l (-41.0%, p<0.001) compared to
women in
placebo group. When stratifying the study population into tertiles of baseline
urinary CTX-ll,
the mean of urinary CTX-II in the different tertiles was 114.6, 197.9 and
385.4 ng/mmol,
respectively. Women in the highest tertile of urinary CTX-II at baseline show
the largest
responses to oral sCT in a dose-dependent manner. Women, who received 1.0 mg
of sCT,
and are in the highest cartilage turnover at baseline, have the greatest
decreases in urinary
CTX-II after 3-month treatment compared to women in the lowest tertile (-36,6%
vs. -9.9%,
p=0.005). Similar trend is observed with 0.4 mg sCT when comparing women in
the highest
tertile of urinary CTX-II to the lowest tertile.
CA 02532565 2006-01-17
WO 2005/014031 PCT/EP2004/008210
-27-
C-telopeptide of type I collagen (CTX I) is considered to be a specific marker
sensitive to
bone resorption; conversely, type li collagen C-telopeptide (CTX-II) is
considered to be a
useful cartilage marker.
Conclusion: Our study strongly suggests that salmon CT may reduce cartilage
degradation
and thereby could provide therapeutic benefits for osteoarthritis in a dose
range of 0.4 to 2.5
mg of salmon calcitonin, more preferably around 1 mg of salmon calcitonin.
